We are pleased to share that the first patient in Kodiak’s phase I trial was treated by Dr. Pravin Dugel of the Retinal Consultants of Arizona. The injection was uneventful. Day 2 assessment was within normal limits with no signs of inflammation and with clear ocular media.
Kodiak is A Phase I Open Label, Multi-center Study to Investigate Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following a Single Intravitreal administration of KSI-301 in Subjects with Center Involved Diabetic Macular Edema (DME).
If you or someone you know is interested in learning more information about this, or our clinical research trials, please call (602) 682-2770.